GlassScriptPhysician profile
Barbara A Moran-Faile
NPI 1396737995
$414.80
in general payments reported to CMS, 2019-2025
12 companies · $49.29 in 2025
The $49.29 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.00 · 2020: $31.10 · 2021: $82.49 · 2022: $89.57 · 2023: $24.72 · 2024: $48.63 · 2025: $49.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $122.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $102.47 | 2019-2022 | |
| Amgen INC. | $60.95 | 2019-2022 | |
| Novo Nordisk INC | $49.29 | 2025 | Ozempic |
| Boston Scientific Corporation | $38.15 | 2019-2024 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $35.94 | 2022 | |
| Daiichi Sankyo INC. | $24.72 | 2023 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $23.69 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $21.94 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.59 | 2019 | |
| Cook Medical LLC | $14.67 | 2019 | |
| Esperion Therapeutics, INC. | $13.44 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Moran-Faile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.